XBB.1.5 vaccine booster shows promise against new Omicron variants in latest study

A study posted to bioRxiv reveals that the monovalent XBB.1.5 vaccine booster significantly boosts neutralizing antibodies against new SARS-CoV-2 Omicron sub-variants. The research shows that both XBB.1.5 vaccination and infection elevate neutralizing titers, with the vaccine being particularly effective in infection-naïve individuals and those previously infected with Omicron.

Elevating Healthcare Through Risk Stratification: Lessons from North Carolina’s Value-Based Initiatives

Kevin Riley, CEO and President, Zyter|TruCare Sheena Ming, Clinical Success Consultant at Zyter|TruCare As the healthcare landscape continues to evolve, there’s a clear trend towards

February 1, 2024

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s (Insulin icodec + Semaglutide)?

(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III program in Type 2 Diabetes.

March 14, 2024

California is investing $500M in therapy apps for youth. Advocates fear it won’t pay off.

With little pomp, California launched two apps at the start of the year offering free behavioral health services to youths to help them cope with

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.